Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Topotecan vs Docetaxel in Second-Line NSCLC
NCT00193245Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Nov 2000
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of topotecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate. Started Nov 2000; status: completed.
02
Drugs
topotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00193245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193245.